Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INMB INmune Bio	$2.34 +13.0%	$6.12	$1.89 ▼ $11.64	$55.18M	1.34	836,080 shs	2.88 million shs
OGI Organigram Global	$1.46 +2.1%	$1.35	$0.85 ▼ $2.08	$195.55M	1.36	699,896 shs	447,606 shs
SLS SELLAS Life Sciences Group	$1.92 +1.1%	$1.77	$0.77 ▼ $2.27	$191.58M	2.31	2.67 million shs	2.38 million shs
YMAB Y-mAbs Therapeutics	$4.35 +3.1%	$4.49	$3.55 ▼ $16.11	$196.99M	0.51	294,223 shs	181,678 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INMB INmune Bio	-2.36%	-10.00%	-73.12%	-71.68%	-78.28%
OGI Organigram Global	-3.38%	0.00%	+2.14%	+37.50%	-16.37%
SLS SELLAS Life Sciences Group	-4.04%	-9.09%	+14.46%	+48.44%	+74.31%
YMAB Y-mAbs Therapeutics	-3.21%	+0.24%	-10.40%	-7.05%	-67.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INMB INmune Bio	2.3087 of 5 stars	3.3	1.0	3.8	1.7	0.6
OGI Organigram Global	1.1396 of 5 stars	0.0	1.0	3.1	0.0	2.5
SLS SELLAS Life Sciences Group	0.3527 of 5 stars	0.0	1.0	2.2	1.7	0.6
YMAB Y-mAbs Therapeutics	4.1493 of 5 stars	4.4	5.0	3.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INMB INmune Bio	2.57	Moderate Buy	$18.40	686.32% Upside
OGI Organigram Global	3.00	Buy	N/A	N/A
SLS SELLAS Life Sciences Group	3.00	Buy	$7.00	264.58% Upside
YMAB Y-mAbs Therapeutics	2.82	Moderate Buy	$15.60	258.62% Upside

Current Analyst Ratings Breakdown

Latest INMB, OGI, SLS, and YMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	SLS SELLAS Life Sciences Group	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $7.00
7/2/2025	INMB INmune Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $8.00
7/1/2025	INMB INmune Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/1/2025	INMB INmune Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Underperform
6/30/2025	INMB INmune Bio	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/29/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$20.00 ➝ $15.00
5/28/2025	YMAB Y-mAbs Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$21.00 ➝ $18.00
5/19/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
5/14/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00
5/14/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00
4/22/2025	YMAB Y-mAbs Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INMB INmune Bio	$10K	5,517.72	N/A	N/A	$1.45 per share	1.61
OGI Organigram Global	$194.09M	1.01	N/A	N/A	$2.07 per share	0.71
SLS SELLAS Life Sciences Group	$1M	191.58	N/A	N/A	$0.13 per share	14.77
YMAB Y-mAbs Therapeutics	$88.66M	2.22	N/A	N/A	$2.05 per share	2.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INMB INmune Bio	-$42.08M	-$1.93	N/A	N/A	N/A	N/A	-119.35%	-89.37%	7/30/2025 (Estimated)
OGI Organigram Global	-$33.39M	$0.10	14.60	N/A	N/A	8.05%	-5.93%	-4.39%	8/12/2025 (Estimated)
SLS SELLAS Life Sciences Group	-$30.88M	-$0.38	N/A	N/A	N/A	N/A	-193.67%	-113.02%	8/12/2025 (Estimated)
YMAB Y-mAbs Therapeutics	-$29.67M	-$0.64	N/A	N/A	N/A	-31.84%	-30.59%	-22.70%	8/11/2025 (Estimated)

Latest INMB, OGI, SLS, and YMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q3 2025	OGI Organigram Global	-$0.01	N/A	N/A	N/A	$68.04 million	N/A
8/12/2025	Q2 2025	SLS SELLAS Life Sciences Group	-$0.0767	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	YMAB Y-mAbs Therapeutics	-$0.27	N/A	N/A	N/A	$18.40 million	N/A
8/7/2025	Q2 2025	INMB INmune Bio	-$0.37	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	SLS SELLAS Life Sciences Group	-$0.1067	-$0.07	+$0.0367	-$0.07	N/A	N/A
5/13/2025	Q1 2025	YMAB Y-mAbs Therapeutics	-$0.22	-$0.12	+$0.10	-$0.12	$19.97 million	$20.90 million
5/8/2025	Q1 2025	INMB INmune Bio	-$0.43	-$0.43	N/A	-$0.43	N/A	$0.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
OGI Organigram Global	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INMB INmune Bio	N/A	2.64	2.64
OGI Organigram Global	N/A	3.42	1.90
SLS SELLAS Life Sciences Group	N/A	4.64	4.64
YMAB Y-mAbs Therapeutics	N/A	4.77	4.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INMB INmune Bio	12.72%
OGI Organigram Global	34.63%
SLS SELLAS Life Sciences Group	17.38%
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
INMB INmune Bio	35.70%
OGI Organigram Global	0.09%
SLS SELLAS Life Sciences Group	1.20%
YMAB Y-mAbs Therapeutics	19.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INMB INmune Bio	10	23.58 million	15.17 million	Optionable
OGI Organigram Global	860	133.94 million	133.82 million	Optionable
SLS SELLAS Life Sciences Group	10	99.78 million	98.58 million	Not Optionable
YMAB Y-mAbs Therapeutics	150	45.28 million	36.36 million	Optionable

INMB, OGI, SLS, and YMAB Headlines

Recent News About These Companies

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Moderate Buy" by Analysts

July 4, 2025 | marketbeat.com

YMAB Y-mAbs Therapeutics, Inc. - Seeking Alpha

June 28, 2025 | seekingalpha.com

Y mAbs Therapeutics News (YMAB) - Investing.com

June 26, 2025 | investing.com

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

June 11, 2025 | finance.yahoo.com

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

May 28, 2025 | globenewswire.com

Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025

May 26, 2025 | insidermonkey.com

Y-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research Meeting

May 26, 2025 | quiverquant.comQ

Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

May 26, 2025 | globenewswire.com

Y-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdles

May 24, 2025 | investing.com

Truist Financial Sticks to Its Buy Rating for Y-Mabs Therapeutics (YMAB)

May 16, 2025 | theglobeandmail.com

Y-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges

May 14, 2025 | finance.yahoo.com

Y-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

May 13, 2025 | finanznachrichten.de

Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025

May 13, 2025 | globenewswire.com

Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

May 13, 2025 | globenewswire.com

Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)

May 7, 2025 | globenewswire.com

Why Y-mAbs Therapeutics, Inc.’s (YMAB) Stock Is Down 5.65%

May 6, 2025 | aaii.comA

Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025

May 6, 2025 | globenewswire.com

Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline

April 29, 2025 | zacks.com

Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA

April 27, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Hot Tech Stocks Showing Bullish Price Action Right Now
By Thomas Hughes | July 11, 2025
View 3 Hot Tech Stocks Showing Bullish Price Action Right Now
Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
By Leo Miller | June 25, 2025
View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
Geospace Stock Skyrockets After Major Petrobras Contract
By Jeffrey Neal Johnson | June 24, 2025
View Geospace Stock Skyrockets After Major Petrobras Contract
Why Occidental's Price Dip Signals a Buying Opportunity
By Jeffrey Neal Johnson | July 3, 2025
View Why Occidental's Price Dip Signals a Buying Opportunity

INMB, OGI, SLS, and YMAB Company Descriptions

INmune Bio NASDAQ:INMB

$2.34 +0.27 (+13.04%)

Closing price 04:00 PM Eastern

Extended Trading

$2.33 -0.01 (-0.64%)

As of 04:31 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Organigram Global NASDAQ:OGI

$1.46 +0.03 (+2.10%)

Closing price 04:00 PM Eastern

Extended Trading

$1.44 -0.01 (-1.03%)

As of 04:21 PM Eastern

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.

SELLAS Life Sciences Group NASDAQ:SLS

$1.92 +0.02 (+1.05%)

Closing price 04:00 PM Eastern

Extended Trading

$1.90 -0.02 (-1.04%)

As of 04:26 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Y-mAbs Therapeutics NASDAQ:YMAB

$4.35 +0.13 (+3.08%)

Closing price 04:00 PM Eastern

Extended Trading

$4.35 0.00 (0.00%)

As of 04:04 PM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time